论文部分内容阅读
目的贝伐单抗联合OHLF3方案治疗晚期胃癌疗效观察。方法 35例晚期胃癌患者采用贝伐单抗进行治疗,同时联合使用OHLF3方案进行化疗,治疗2年后观察患者的临床治疗效果。结果治疗2年后,35例患者中治疗总反应率为71.43%,患者完全缓解率为25.71%,患者出现的不良反应主要表现为白细胞减少、呕吐、腹泻、神经毒性等,但是在治疗停止后,患者的不良反应症状明显减轻,之后消失,在整个治疗过程中没有出现明显的不良反应症状。患者的生活质量得到明显改善。结论在晚期胃癌患者治疗过程中,采用贝伐单抗联合OHLF3方案进行治疗,能够有效地改善患者的生活质量,降低不良反应的发生率,值得在临床上推广应用。
Therapeutic effect of bevacizumab combined with OHLF3 in the treatment of advanced gastric cancer. Methods 35 cases of advanced gastric cancer patients treated with bevacizumab, combined with OHLF3 regimen chemotherapy, 2 years after treatment to observe the clinical effect of the patients. Results After 2 years of treatment, the overall response rate was 71.43% in 35 patients, and the complete remission rate was 25.71%. The adverse reactions in patients were mainly leucopenia, vomiting, diarrhea and neurotoxicity. However, after the treatment was stopped , The symptoms of adverse reactions in patients significantly reduced, then disappear, in the course of the entire treatment did not appear obvious symptoms of adverse reactions. The quality of life of patients has been significantly improved. Conclusion The treatment of advanced gastric cancer patients with bevacizumab combined with OHLF3 regimen can effectively improve the quality of life of patients and reduce the incidence of adverse reactions, it is worth in the clinical application.